Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Macaluso

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Personality Disorders|December 8, 2017
Introduction of the DSM-5 levels of Personality Functioning QuestionnaireSteven K Huprich, Sharon M Nelson, Kevin B Meehan, et al.
JAMA Psychiatry|July 2, 2025
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical TrialAdam Janik, Xin Qiu, Rosanne Lane, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2022
RORγt-Expressing Pathogenic CD4<sup>+</sup> T Cells Cause Brain Inflammation during Chronic ColitisMichel Edwar Mickael, Suniti Bhaumik, Ayanabha Chakraborti, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|April 17, 2021
Psychiatry Milestones 2.0: Using the Supplemental Guide to Create a Shared Model of the Development of Professional Identity and ExpertiseJ Mark Kinzie, Sandra M DeJong, Laura Edgar, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|July 10, 2020
The Psychiatry Milestones 2.0: How Did We Get from 1.0 to 2.0 and What Can Users Expect?Matthew Macaluso, Mark Kinzie, Deborah Cowley, et al.
Psychopharmacology Bulletin|December 10, 2021
Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED StudyJess G Fiedorowicz, Lisa Brown, James Li, et al.
The Journal of Clinical Psychiatry|May 7, 2026
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized TrialSamuel T Wilkinson, Brandon M Kitay, Matthew Macaluso, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|October 30, 2020
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depressionMaurizio Fava, Erica Mazzone, Marlene Freeman, et al.
Psychiatry Research|November 7, 2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocolBrandon M Kitay, Eva Murphy, Matthew Macaluso, et al.
BMC Psychiatry|December 29, 2019
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBoadie W Dunlop, Sagar V Parikh, Anthony J Rothschild, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Personality Disorders|December 8, 2017
Introduction of the DSM-5 levels of Personality Functioning QuestionnaireSteven K Huprich, Sharon M Nelson, Kevin B Meehan, et al.
JAMA Psychiatry|July 2, 2025
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical TrialAdam Janik, Xin Qiu, Rosanne Lane, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 5, 2022
RORγt-Expressing Pathogenic CD4<sup>+</sup> T Cells Cause Brain Inflammation during Chronic ColitisMichel Edwar Mickael, Suniti Bhaumik, Ayanabha Chakraborti, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|April 17, 2021
Psychiatry Milestones 2.0: Using the Supplemental Guide to Create a Shared Model of the Development of Professional Identity and ExpertiseJ Mark Kinzie, Sandra M DeJong, Laura Edgar, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|July 10, 2020
The Psychiatry Milestones 2.0: How Did We Get from 1.0 to 2.0 and What Can Users Expect?Matthew Macaluso, Mark Kinzie, Deborah Cowley, et al.
Psychopharmacology Bulletin|December 10, 2021
Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED StudyJess G Fiedorowicz, Lisa Brown, James Li, et al.
The Journal of Clinical Psychiatry|May 7, 2026
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized TrialSamuel T Wilkinson, Brandon M Kitay, Matthew Macaluso, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|October 30, 2020
Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depressionMaurizio Fava, Erica Mazzone, Marlene Freeman, et al.
Psychiatry Research|November 7, 2023
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocolBrandon M Kitay, Eva Murphy, Matthew Macaluso, et al.
BMC Psychiatry|December 29, 2019
Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trialBoadie W Dunlop, Sagar V Parikh, Anthony J Rothschild, et al.
Pageof 7